Dianne Griffis
About Dianne Griffis
Dianne Griffis is the Senior Director of Clinical Development at Insmed Incorporated, with extensive experience in regulatory submissions and product approvals in the pharmaceutical industry. She has held various leadership roles at AstraZeneca and GlaxoSmithKline, focusing on therapeutic areas such as Respiratory, Rare Disease, Immunology, and Neuroscience.
Current Role at Insmed
Dianne Griffis serves as the Senior Director of Clinical Development at Insmed Incorporated. She has held this position since 2023, contributing her expertise in clinical trials and regulatory submissions. Her role involves overseeing clinical development strategies and ensuring compliance with industry regulations.
Previous Experience at AstraZeneca
Before joining Insmed, Dianne Griffis worked at AstraZeneca in various capacities. She served as Senior Group Director for Late Respiratory and Immunology from 2021 to 2023 and as Global Clinical Program Lead for four months in 2023. Her tenure at AstraZeneca included significant responsibilities in managing clinical programs and regulatory submissions.
Experience at GlaxoSmithKline
Dianne Griffis has extensive experience at GlaxoSmithKline, where she held multiple roles from 2004 to 2015. She worked as a Senior Clinical Development Scientist, Clinical Development Manager, and Lead Clinical Development Scientist. Her work involved managing clinical trials and contributing to product development in the pharmaceutical sector.
Educational Background
Dianne Griffis has a strong academic background. She achieved a PhD in BioPsychology from Virginia Commonwealth University in 1995. Additionally, she studied Pharmacology at the University of Pennsylvania and holds a BA in Psychology from Catawba College, obtained in 1991. This educational foundation supports her expertise in clinical development.
Therapeutic Expertise and Skills
Dianne Griffis possesses therapeutic expertise in Respiratory, Rare Disease, Immunology, and Neuroscience. She has extensive experience managing clinical trials involving inhalers and biologics across Phases 2, 3, and 4. Her strong background in regulatory submissions and product approvals enhances her effectiveness in clinical development.